Phenotypic and functional dysregulated blood NK cells in Colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15.

Phenotypic and functional dysregulated blood NK cells in Colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15.

The clinical outcome of colorectal cancer (CRC) is associated with the immune response, thus these tumors could be responsive to different immune therapy approaches. NK cells are key anti-tumor primary effectors that can eliminate CRC cells without prior immunization. We previously determined that N...

Full description

Bibliographic Details
Main Authors: Yamila Sol Rocca, María Paula Roberti, Estefanía Paula Juliá, María Betina Pampena, Luisina Bruno, Sergio Rivero, Eduardo Huertas, Fernando Sánchez Loria, Alejandro Pairola, Anne Caignard, José Mordoh, Estrella Mariel Levy
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-10-01
Series:Frontiers in Immunology
Subjects:
colorectal cancer
IL-2
cetuximab
Natural Killer cells
IL-15
NKp46
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00413/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00413/full

Similar Items